Axa
XFOR icon

Axa’s X4 Pharmaceuticals XFOR Stock Holding History

Axa’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,037
Closed -$163K – 1184
2025
Q1 		$163K Sell
23,037
-79,368
-78% -$1.09M ﹤0.01% 1031
2024
Q4 		$2.25M Sell
102,405
-160
-0.2% -$2.55K 0.01% 732
2024
Q3 		$2.06M Buy
102,565
+29
+0% +$605 0.01% 735
2024
Q2 		$1.78M Buy
102,536
+57
+0.1% +$1.86K 0.01% 786
2024
Q1 		$4.27M Buy
102,479
+28
+0% +$779 0.01% 592
2023
Q4 		$2.58M Sell
102,451
-2,478
-2% -$60.3K 0.01% 689
2023
Q3 		$3.43M Sell
104,929
-9,237
-8% -$403K 0.01% 609
2023
Q2 		$6.64M Sell
114,166
-32,383
-22% -$1.66M 0.02% 488
2023
Q1 		$3.82M Buy
146,549
+1,161
+0.8% +$34K 0.01% 629
2022
Q4 		$4.33M Buy
145,388
+7,839
+6% +$371K 0.02% 638
2022
Q3 		$7.06M Buy
137,549
+99,200
+259% +$3.43M 0.03% 504
2022
Q2 		$1.11M Sell
38,349
-29
-0.1% -$1.1K ﹤0.01% 862
2022
Q1 		$2.01M Sell
38,378
-16
-0% -$918 0.01% 823
2021
Q4 		$2.64M Buy
38,394
+18,718
+95% +$2.37M 0.01% 798
2021
Q3 		$3.12M Buy
19,676
+729
+4% +$120K 0.01% 776
2021
Q2 		$3.69M Sell
18,947
-15
-0.1% -$3.77K 0.01% 776
2021
Q1 		$4.9M Sell
18,962
-5
-0% -$1.31K 0.01% 717
2020
Q4 		$3.66M Buy
18,967
+764
+4% +$150K 0.01% 754
2020
Q3 		$3.7M Buy
18,203
+819
+5% +$196K 0.01% 705
2020
Q2 		$4.86M Buy
17,384
+645
+4% +$177K 0.02% 624
2020
Q1 		$5.02M Buy
+16,739
New +$4.75M 0.03% 520

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Axa's XFOR Position: Q2 2025 in Review

Axa sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 23,037 shares — an estimated $163K sold.

Axa first reported a position in XFOR in Q1 2020 and held it in 21 quarters. The position peaked at $7.06M in Q3 2022. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

  • Axa reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Axa sold 23,037 X4 Pharmaceuticals shares in Q2 2025, an estimated $163K.
  • Axa first reported a position in X4 Pharmaceuticals in Q1 2020 and held it in 21 quarters.
  • Axa's X4 Pharmaceuticals position peaked at $7.06M in Q3 2022.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on Axa's 13F filing for Q2 2025, filed 14 Aug 2025.